Connor, Clark & Lunn Investment Management (CC&L)
ZNTL icon

Connor, Clark & Lunn Investment Management (CC&L)’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.68M Sell
758,033
-33,968
-4% -$136K 0.01% 822
2026
Q1 		$1.85M Buy
792,001
+4,946
+0.6% +$12.8K ﹤0.01% 982
2025
Q4 		$1.06M Buy
787,055
+406,233
+107% +$591K ﹤0.01% 1111
2025
Q3 		$575K Buy
380,822
+65,977
+21% +$98.9K ﹤0.01% 1219
2025
Q2 		$365K Sell
314,845
-46,391
-13% -$61.2K ﹤0.01% 1320
2025
Q1 		$574K Buy
361,236
+16,197
+5% +$34.9K ﹤0.01% 1104
2024
Q4 		$1.05M Buy
345,039
+115,901
+51% +$380K ﹤0.01% 917
2024
Q3 		$843K Buy
229,138
+127,868
+126% +$465K ﹤0.01% 935
2024
Q2 		$414K Buy
101,270
+81,799
+420% +$914K ﹤0.01% 1097
2024
Q1 		$307K Buy
+19,471
New +$268K ﹤0.01% 1256

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s ZNTL Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Zentalis Pharmaceuticals (ZNTL) stake by 4.3% in Q2 2026, selling an estimated $136K and leaving 758,033 shares worth $3.68M. The position accounts for 0.01% of the portfolio, ranked #822.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in ZNTL in Q1 2024 and has held it in 10 quarters since. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 758,033 shares of Zentalis Pharmaceuticals worth $3.68M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 33,968 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $136K.
  • Zentalis Pharmaceuticals made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #822 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Zentalis Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.